BR112016014182A2 - Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso - Google Patents
Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervosoInfo
- Publication number
- BR112016014182A2 BR112016014182A2 BR112016014182A BR112016014182A BR112016014182A2 BR 112016014182 A2 BR112016014182 A2 BR 112016014182A2 BR 112016014182 A BR112016014182 A BR 112016014182A BR 112016014182 A BR112016014182 A BR 112016014182A BR 112016014182 A2 BR112016014182 A2 BR 112016014182A2
- Authority
- BR
- Brazil
- Prior art keywords
- nervous system
- fatty acids
- omega
- compositions
- diseases involving
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 210000000653 nervous system Anatomy 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940012843 omega-3 fatty acid Drugs 0.000 title abstract 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 title abstract 3
- 239000006014 omega-3 oil Substances 0.000 title abstract 3
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
COMPOSIÇÕES DE ÁCIDOS GRAXOS ÔMEGA 3 PARA TRATAR DOENÇAS QUE ENVOLVEM DANOS AO SISTEMA NERVOSO, composições que incluem ácidos graxos ômega 3 para uso no tratamento, melhoria ou prevenção de várias condições, desordens e doenças que envolvem danos ao sistema nervoso, como a neuropatia do sistema nervoso periférico e o glaucoma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/077356 WO2015090394A1 (en) | 2013-12-19 | 2013-12-19 | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016014182A2 true BR112016014182A2 (pt) | 2017-08-08 |
Family
ID=50137601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016014182A BR112016014182A2 (pt) | 2013-12-19 | 2013-12-19 | Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso |
Country Status (24)
Country | Link |
---|---|
US (2) | US20160331712A1 (pt) |
EP (1) | EP3082795B1 (pt) |
JP (1) | JP6389893B2 (pt) |
KR (1) | KR101898358B1 (pt) |
CN (1) | CN105828813A (pt) |
AU (1) | AU2013407946B2 (pt) |
BR (1) | BR112016014182A2 (pt) |
CA (1) | CA2934600C (pt) |
CY (1) | CY1123942T1 (pt) |
DK (1) | DK3082795T3 (pt) |
ES (1) | ES2813383T3 (pt) |
HR (1) | HRP20201221T1 (pt) |
HU (1) | HUE050205T2 (pt) |
IL (1) | IL246254B (pt) |
LT (1) | LT3082795T (pt) |
MX (1) | MX2016007803A (pt) |
MY (1) | MY185412A (pt) |
PH (1) | PH12016501159A1 (pt) |
PL (1) | PL3082795T3 (pt) |
PT (1) | PT3082795T (pt) |
RS (1) | RS60862B1 (pt) |
RU (1) | RU2667640C1 (pt) |
UA (1) | UA117274C2 (pt) |
WO (1) | WO2015090394A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
JP2022554277A (ja) * | 2019-10-30 | 2022-12-28 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
KR20220143685A (ko) | 2020-02-06 | 2022-10-25 | 퍼퓨즈 세라퓨틱스, 인크. | 안질환의 치료를 위한 조성물 |
MX2023012723A (es) | 2021-04-30 | 2024-02-08 | Perfuse Therapeutics Inc | Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
JP5240757B2 (ja) * | 2005-02-22 | 2013-07-17 | 持田製薬株式会社 | 神経再生促進剤 |
WO2007081773A2 (en) * | 2006-01-05 | 2007-07-19 | Reliant Pharmaceuticals, Inc | Treatment of fatty liver |
EP1900378A1 (en) | 2006-08-31 | 2008-03-19 | Novartis AG | Pharmaceutical compositions for the treatment of fungal infections |
WO2010018856A1 (ja) * | 2008-08-13 | 2010-02-18 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
US9062275B2 (en) * | 2009-04-17 | 2015-06-23 | Natac Pharma, S.L. | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
BR112013018839A2 (pt) * | 2011-01-25 | 2016-09-27 | Nestec Sa | métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais |
RU2013142437A (ru) * | 2011-02-18 | 2015-03-27 | Нестек С.А. | Способы и композиции для лечения, снижения или предупреждения повреждения нервной системы животных |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
KR101629670B1 (ko) * | 2011-09-12 | 2016-06-13 | 타소스 지오지우 | 질환을 치료하기 위한 오메가 지방산의 용도 |
-
2013
- 2013-12-19 ES ES13830184T patent/ES2813383T3/es active Active
- 2013-12-19 MX MX2016007803A patent/MX2016007803A/es unknown
- 2013-12-19 MY MYPI2016702245A patent/MY185412A/en unknown
- 2013-12-19 CN CN201380081739.3A patent/CN105828813A/zh active Pending
- 2013-12-19 US US15/106,475 patent/US20160331712A1/en not_active Abandoned
- 2013-12-19 JP JP2016540609A patent/JP6389893B2/ja active Active
- 2013-12-19 EP EP13830184.1A patent/EP3082795B1/en active Active
- 2013-12-19 CA CA2934600A patent/CA2934600C/en active Active
- 2013-12-19 UA UAA201607999A patent/UA117274C2/uk unknown
- 2013-12-19 PL PL13830184T patent/PL3082795T3/pl unknown
- 2013-12-19 DK DK13830184.1T patent/DK3082795T3/da active
- 2013-12-19 LT LTEP13830184.1T patent/LT3082795T/lt unknown
- 2013-12-19 BR BR112016014182A patent/BR112016014182A2/pt not_active Application Discontinuation
- 2013-12-19 PT PT138301841T patent/PT3082795T/pt unknown
- 2013-12-19 RS RS20200971A patent/RS60862B1/sr unknown
- 2013-12-19 HU HUE13830184A patent/HUE050205T2/hu unknown
- 2013-12-19 RU RU2016129079A patent/RU2667640C1/ru active
- 2013-12-19 WO PCT/EP2013/077356 patent/WO2015090394A1/en active Application Filing
- 2013-12-19 KR KR1020167019609A patent/KR101898358B1/ko active IP Right Grant
- 2013-12-19 AU AU2013407946A patent/AU2013407946B2/en active Active
-
2016
- 2016-06-15 PH PH12016501159A patent/PH12016501159A1/en unknown
- 2016-06-15 IL IL246254A patent/IL246254B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,354 patent/US10905671B2/en active Active
-
2020
- 2020-08-04 HR HRP20201221TT patent/HRP20201221T1/hr unknown
- 2020-08-13 CY CY20201100758T patent/CY1123942T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN105828813A (zh) | 2016-08-03 |
KR20160093729A (ko) | 2016-08-08 |
WO2015090394A1 (en) | 2015-06-25 |
AU2013407946A2 (en) | 2016-08-25 |
UA117274C2 (uk) | 2018-07-10 |
LT3082795T (lt) | 2020-11-10 |
RU2016129079A (ru) | 2018-01-24 |
AU2013407946B2 (en) | 2017-09-07 |
CA2934600C (en) | 2018-11-20 |
PH12016501159A1 (en) | 2016-08-15 |
EP3082795B1 (en) | 2020-05-20 |
KR101898358B1 (ko) | 2018-09-12 |
AU2013407946A1 (en) | 2016-08-04 |
CA2934600A1 (en) | 2015-06-25 |
IL246254A0 (en) | 2016-07-31 |
US20190192466A1 (en) | 2019-06-27 |
RS60862B1 (sr) | 2020-11-30 |
RU2667640C1 (ru) | 2018-09-21 |
US20160331712A1 (en) | 2016-11-17 |
HUE050205T2 (hu) | 2020-11-30 |
ES2813383T3 (es) | 2021-03-23 |
PL3082795T3 (pl) | 2020-11-16 |
MY185412A (en) | 2021-05-18 |
PT3082795T (pt) | 2020-08-27 |
US10905671B2 (en) | 2021-02-02 |
HRP20201221T1 (hr) | 2020-11-13 |
JP6389893B2 (ja) | 2018-09-12 |
EP3082795A1 (en) | 2016-10-26 |
MX2016007803A (es) | 2017-08-10 |
DK3082795T3 (da) | 2020-08-24 |
IL246254B (en) | 2021-04-29 |
CY1123942T1 (el) | 2022-03-24 |
JP2017501169A (ja) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
CR20150476A (es) | Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
GT201300209A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
CY1123942T1 (el) | Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα | |
BR112016023815A2 (pt) | composições tópicas para o alívio da dor, produção e uso | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
AR105913A1 (es) | Composiciones de micropartículas que comprenden saflufenacil | |
CO7350653A2 (es) | Retinoides y uso de los mismos | |
BR112017024304A2 (pt) | processo para a preparação de um extrato de cérebro animal | |
BR112015016391A2 (pt) | carboxamidas i baseadas em pirazolil como inibidoras do canal crac | |
CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante | |
BR112015016394A2 (pt) | carboxamidas ii baseadas em pirazolil como inibidoras do canal crac | |
BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/202 (2006.01), A61P 25/00 (2006.01), A61P |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |